DURECT Corp. (DRRX:NASDAQ) announced in a news release that its abstract concerning results from its recently completed Phase 2a study of DUR-928 in patients with alcoholic hepatitis was chosen to be presented orally at The Liver Meeting 2019's late breaking session. Dr. Tarek Hassanein, one of the Phase 2a trial's principal investigators, gave the presentation.
"These compelling data provide strong rationale for continued development, and we plan to initiate a Phase 2b study for this difficult to treat and life threatening condition next year," President and CEO James E. Brown said in the release.
DURECT's abstract, along with 28 other late breaking ones, was picked for presentation from 3,000 entries.
Separately, Dr. Craig McClain presented in a poster session a comparison of data from the Phase 2a clinical trial of DUR-928 and those from a control group in an alcoholic hepatitis trial done at the University of Louisville.
The company's study results also were chosen to be included in the "Best of The Liver Meeting" summary slide presentation in the alcohol-related liver disease category. The Liver Meeting, the American Association for the Study of Liver Diseases' annual conference, was held Nov. 8 to 12, 2019, in Boston, Mass.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: DURECT. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
